Loading clinical trials...
Loading clinical trials...
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Conditions
Interventions
Exemestane
Abiraterone acetate + Prednisone/ Prednisolone + Exemestane
+1 more
Locations
81
United States
Muscle Shoals, Alabama, United States
Fresno, California, United States
Los Angeles, California, United States
Monterey, California, United States
Chicago, Illinois, United States
Waterville, Maine, United States
Start Date
August 24, 2011
Primary Completion Date
July 28, 2014
Completion Date
August 8, 2018
Last Updated
April 11, 2019
NCT06995482
NCT06767150
NCT07253493
NCT04893226
NCT07022925
NCT05575167
Lead Sponsor
Janssen Research & Development, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions